company background image
NRIX logo

Nurix Therapeutics NasdaqGM:NRIX Stock Report

Last Price

US$20.27

Market Cap

US$1.5b

7D

-5.1%

1Y

123.2%

Updated

13 Dec, 2024

Data

Company Financials +

Nurix Therapeutics, Inc.

NasdaqGM:NRIX Stock Report

Market Cap: US$1.5b

NRIX Stock Overview

A clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. More details

NRIX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Nurix Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Nurix Therapeutics
Historical stock prices
Current Share PriceUS$20.27
52 Week HighUS$29.56
52 Week LowUS$7.65
Beta2.11
1 Month Change-25.34%
3 Month Change-18.27%
1 Year Change123.24%
3 Year Change-28.27%
5 Year Changen/a
Change since IPO6.63%

Recent News & Updates

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Nov 07
Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Oct 31
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Recent updates

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Nov 07
Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Oct 31
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Nurix: An Attractive Early-Stage Biotech Play

Oct 08

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Sep 07
Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Sep 04

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Jul 15
Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

May 29
What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Apr 15

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Apr 14
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20
Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14
Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13
Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30
Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18
Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28
We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21
We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Mar 07
We Think Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Drive Business Growth

Nurix: Advancing Targeted Protein Modulation Therapies

Nov 21

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

Nov 21
Companies Like Nurix Therapeutics (NASDAQ:NRIX) Can Afford To Invest In Growth

Shareholder Returns

NRIXUS BiotechsUS Market
7D-5.1%-2.7%-0.4%
1Y123.2%3.3%27.7%

Return vs Industry: NRIX exceeded the US Biotechs industry which returned 3.3% over the past year.

Return vs Market: NRIX exceeded the US Market which returned 27.7% over the past year.

Price Volatility

Is NRIX's price volatile compared to industry and market?
NRIX volatility
NRIX Average Weekly Movement8.1%
Biotechs Industry Average Movement10.3%
Market Average Movement6.3%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.1%

Stable Share Price: NRIX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: NRIX's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2009284Arthur Sandswww.nurixtx.com

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases.

Nurix Therapeutics, Inc. Fundamentals Summary

How do Nurix Therapeutics's earnings and revenue compare to its market cap?
NRIX fundamental statistics
Market capUS$1.46b
Earnings (TTM)-US$176.98m
Revenue (TTM)US$56.42m

25.4x

P/S Ratio

-8.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NRIX income statement (TTM)
RevenueUS$56.42m
Cost of RevenueUS$204.12m
Gross Profit-US$147.70m
Other ExpensesUS$29.28m
Earnings-US$176.98m

Last Reported Earnings

Aug 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.50
Gross Margin-261.76%
Net Profit Margin-313.65%
Debt/Equity Ratio0%

How did NRIX perform over the long term?

See historical performance and comparison